Compare · CELL vs GRPH
CELL vs GRPH
Side-by-side comparison of PhenomeX Inc. (CELL) and Graphite Bio Inc. (GRPH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELL and GRPH operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- GRPH has more recent analyst coverage (16 ratings vs 0 for CELL).
- Company
- PhenomeX Inc.
- Graphite Bio Inc.
- Price
- -
- -
- Market cap
- -
- -
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 0
- 16
Graphite Bio Inc.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expression; GPH201 for the treatment of X-linked severe combined immunodeficiency syndrome; and GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme. The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020. Graphite Bio, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Latest CELL
- PhenomeX Announces Opto® Memory B Discovery Human Workflow on the Beacon® Optofluidic Platform
- PhenomeX Announces The Release Of SpotLight Human Lambda Reagent For The Beacon Platform To Accelerate Cell Line Development Workflows
- PhenomeX Announces the Release of SpotLight™ Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows
- PhenomeX to Participate in Upcoming Cell Biology Conferences
- PhenomeX Unveils Meteor Chips For Quantitative Bulk Analysis On The IsoSpark Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomic
- PhenomeX Unveils Meteor™ Chips For Quantitative Bulk Analysis On The IsoSpark™ Platform To Revolutionize High Throughput Multiplexed Hands-Free Proteomics
- PhenomeX Inc. Announces Commencement of Cash Tender Offer by Bruker
- Cathie Wood's Bullish Stance on Flying Cars: Ark Buys $3.9M Worth of Archer Aviation Shares
- Lifshitz Law PLLC Announces Investigations of TMBR, PR, ESTE, and CELL
- Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2023
Latest GRPH
- Mccollum James W bought $501,093 worth of shares (31,332 units at $15.99) (SEC Form 4)
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form 10-Q filed by Graphite Bio Inc.
- Graphite Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form EFFECT filed by Graphite Bio Inc.
- SEC Form 424B3 filed by Graphite Bio Inc.
- SEC Form SC 13G/A filed by Graphite Bio Inc. (Amendment)
- Graphite Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form S-1 filed by Graphite Bio Inc.
- New insider Alpha Wave Ventures Gp, Ltd claimed ownership of 3,612,211 shares (SEC Form 3)